Adage Capital Partners
KPTI icon

Adage Capital Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Adage Capital Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Sell
1,521,322
-285,000
-16% -$2.47M 0.02% 603
2026
Q1 		$10.1M Buy
1,806,322
+1,385,000
+329% +$10.6M 0.02% 686
2025
Q4 		$3.1M Hold
421,322
– – ﹤0.01% 809
2025
Q3 		$2.76M Hold
421,322
– – ﹤0.01% 784
2025
Q2 		$1.82M Hold
421,322
– – ﹤0.01% 767
2025
Q1 		$1.58M Sell
421,322
-1
-0% -$9 ﹤0.01% 774
2024
Q4 		$4.27M Buy
421,323
+133,334
+46% +$1.61M 0.01% 730
2024
Q3 		$3.59M Hold
287,989
– – 0.01% 744
2024
Q2 		$3.75M Buy
287,989
+54,656
+23% +$905K 0.01% 738
2024
Q1 		$5.29M Buy
233,333
+122,446
+110% +$2.15M 0.01% 691
2023
Q4 		$1.44M Buy
+110,887
New +$1.49M ﹤0.01% 752
2023
Q1 		– Sell
-51,381
Closed -$2.62M – 956
2022
Q4 		$2.62M Buy
+51,381
New +$3.56M 0.01% 798
2021
Q2 		– Sell
-89,987
Closed -$14.2M – 1039
2021
Q1 		$14.2M Sell
89,987
-74,346
-45% -$15.7M 0.03% 571
2020
Q4 		$38.2M Sell
164,333
-49,862
-23% -$11.6M 0.08% 262
2020
Q3 		$46.9M Sell
214,195
-2,388
-1% -$584K 0.12% 185
2020
Q2 		$61.5M Sell
216,583
-31,652
-13% -$9.36M 0.16% 150
2020
Q1 		$71.5M Sell
248,235
-4,232
-2% -$1.17M 0.21% 116
2019
Q4 		$72.6M Buy
252,467
+139,134
+123% +$30.2M 0.18% 146
2019
Q3 		$16.4M Buy
+113,333
New +$15.4M 0.04% 412

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Adage Capital Partners's KPTI Position: Q2 2026 in Review

Adage Capital Partners reduced its Karyopharm Therapeutics (KPTI) stake by 16% in Q2 2026, selling an estimated $2.47M and leaving 1,521,322 shares worth $14.9M. The position accounts for 0.02% of the portfolio, ranked #603.

Adage Capital Partners first reported a position in KPTI in Q3 2019 and has held it in 19 quarters since. The position peaked at $72.6M in Q4 2019. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Adage Capital Partners held 1,521,322 shares of Karyopharm Therapeutics worth $14.9M as of Q2 2026.
  • Adage Capital Partners sold 285,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $2.47M.
  • Karyopharm Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #603 holding.
  • Adage Capital Partners first reported a position in Karyopharm Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • Adage Capital Partners's Karyopharm Therapeutics position peaked at $72.6M in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.